Avivagen Completes Private Placement
Friday, 26 October 2012 05:59 PM
OTTAWA, ONTARIO, October 26, 2012 - Avivagen Inc. (TSXV:VIV), a wellness company, today announced that it has issued a total of 5,071,429 common shares and an equal number of common share purchase warrants for gross proceeds of $355,000 through a non-brokered private placement.
This private placement involved the sale of units, each comprised of one common share and one common share purchase warrant, for a unit price of $0.07. Each warrant entitles the holder to acquire one common share of Avivagen at an additional purchase price of $0.10 per share for three years from closing.
In connection with the placement Avivagen also issued a total of 285,714 common shares and 571,429 warrants to agents as commissions for their efforts. The warrants are on the same terms as the warrants issued to subscribers.
The net proceeds of the proposed offering will be used to fund working capital and research and development expenditures and for general corporate purposes.
Avivagen CEO, Mr. David Hankinson, commented: "We are very pleased this round of investment includes Avivagen's first institutional investor. This marks an important milestone, confirming the progress the company has already made towards commercialization of its products. The funds will help accelerate commercialization of the companion animal and the food animal safety and productivity products."
The securities issued under this private placement are and will be subject to restrictions on transfer, including a hold period ending four months after issuance. The private placement remains subject to TSX Venture Exchange approval. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities.
About Avivagen
Avivagen, a wellness company, is developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.avivagen.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
David HankinsonGraham Burton, PhD
CEO, Avivagen Inc.President and Co-Founder, Avivagen Inc.
Phone: 902-825-9270Phone: 613-990-0969
[email protected]@avivagen.com
-
